NewsRoom Articles - Page 27 of 46

ThursdayMar 16, 2023 10:30 am

8X Upside Projected for Freight Technologies, Inc. (NASDAQ: FRGT)

Leading Investment Research Firm Maintains Buy Rating Citing strong revenue growth and expectations to ramp through 2025, Chardan Capital Research just issued a new report maintaining its buy rating for Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) and pegs the stock at about 8X current levels. In the report, Chardan states in part, “… Freight Technologies is applying a proven solution to a legacy sector; upside remains compelling from current levels.” A big part of what makes Freight Technologies so compelling is the transformative nature of its technology that’s modernizing the antiquated systems of an extremely important industry – cross border North…

TuesdayMar 14, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Encouraged by Positive Findings from its DIAB-A22-1 Animal Model Study on Potential DehydraTECH-CBD(TM) Treatment for Diabetes

Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more With its unique product offering, a growing list of patents, and…

FridayMar 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Additional Findings From Human Clinical Study, Demonstrating DehydraTECH(TM)-CBD Effects on Hypertension

The global antihypertensive drugs market was valued at around $20.5 billion in 2021 and is expected to reach $39.5 billion by 2030, growing at a CAGR of 2.95% Lexaria’s patented DehydraTECH(TM) technology is designed to formulate and deliver lipophilic drugs and active pharmaceutical ingredients (“APIs”), increasing effectiveness and improving how drugs are delivered into the bloodstream DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, or oral suspensions Lexaria is continuing to evaluate the results of its HYPER-H21-4 human clinical study and will report additional findings as they become…

WednesdayMar 08, 2023 9:00 am

Freight Technologies Inc. (NASDAQ: FRGT) Making Fleet Tracking Technology More Accessible to Consumers; Grows its Fr8Fleet Size and Strengthens Fleet Management Offering

Freight Technologies Inc. (Fr8Tech), a company developing solutions to optimize and automate the supply chain process, believes that technology can help streamline operations, improve safety, and increase efficiency within the fleet-tracking industry This outlook has informed the innovation and overall improvement of its fleet management offering, guaranteed improved customer service, and reduced operational costs, and contributing to the company’s growth Fr8Tech’s management is optimistic that as more people get to know and appreciate fleet technology, the company will continue to experience a steady and sustained growth in demand for its offerings, ultimately defining it as the go-to brand and platform…

TuesdayMar 07, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms, Holds Discussions With Several Larger Companies on Path to Commercialization of DehydraTECH(TM) Technology

Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients The company out-licenses the use of its patented DehydraTECH(TM) technology within the pharmaceutical industry and consumer sectors Lexaria has focused on applied R&D to establish areas of investigation for commercial pursuits, with its programs proving successful Additionally, Lexaria has a robust intellectual property portfolio with 28 patents granted worldwide as of February 2023 In 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator developing and commercializing its…

ThursdayMar 02, 2023 10:30 am

Freight Technologies Inc.’s (NASDAQ: FRGT) Majoba Logistics Partner to Expand Carrier Capacity of Fr8Fleet Product

Freight Technologies, a technology company developing solutions to optimize and automate the supply chain process, has developed a B2B cross-border shipping freight matching platform through its subsidiary Freight App Inc. (“Fr8App”) The freight matching platform, known as Fr8App, supports several solutions, including Fr8Fleet, which enables shippers to secure freight capacity over time rather than on a trip-by-trip basis Fr8Fleet solves multiple problems faced by carriers and shippers, and has gained traction since its release in 2022 Most recently, Fr8App announced a partnership with Majoba Logistics, a leading transportation company in Mexico, to increase the volume of trucks available for Fr8Fleet…

ThursdayMar 02, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Disrupt Drug Delivery Through Innovation

Lexaria's DehydraTECH(TM) technology has 28 granted patents, with many more patents pending worldwide DehydraTECH(TM) uses a patented formulation and dehydration process method to change how the body detects and absorbs drugs Lexaria is focusing on three main areas: CBD for hypertension, oral nicotine to replace vaping and smoking, and CBD potentially for diabetes and seizures Lexaria is conducting early work to support its FDA-registered IND program to investigate DehydraTECH(TM)-processed CBD for hypertension Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability and improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through its…

MondayFeb 27, 2023 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Additional HYPER-H21-4 Study Findings Offer Better Understanding of the Anti-Hypertensive Effects of DehydraTECH-CBD

Dosing for Lexaria’s ambitious and most comprehensive clinical study, HYPER-H21-4, was successfully completed in July 2022, with newly analyzed results now emerging Its latest findings bring the company closer to its upcoming FDA Phase 1b study while also explaining the patented DehydraTECH-(TM)-processed CBD interaction with the sympatho-chromaffin system via catestatin modulation Lexaria’s management is optimistic that DehyraTECH-CBD and its effectiveness in modulating catestatin levels could become a significant value enhancer should it eventually enter the marketplace as an approved hypertension treatment Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, kicked off its human clinical study, HYPER-H21-1 in…

MondayFeb 27, 2023 9:00 am

Freight Technologies Inc. (NASDAQ: FRGT) Jumps Revenue Guidance for 2023 Amid New Optimism for Commercial Truck Transport, Tracking Tools

B2B marketplace builder Freight Technologies Inc. is an innovator in resources for strengthening commercial supply chain transports between the United States, Canada and Mexico Freight Technologies, also known as Fr8Tech, has developed its AI-powered Fr8App resource to provide shippers and carriers with the tools they need for monitoring shipments and vehicle performance, and improving efficiency In this month’s State of the Union address, President Joe Biden restated his administration’s commitment to boosting manufacturing close to home through policies that sustain price competitiveness and respect for quality employment Amid optimism for U.S. trade and labor policies, Fr8Tech recently announced revenue projections…

ThursdayFeb 23, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking Forward to 2023 Goals for Patented DehydraTECH(TM) Technology

Lexaria’s 2022 R&D efforts saw high levels of success, establishing the company as one of the world’s leaders in the investigation of CBD for controlling human blood pressure and, separately, demonstrating performance enhancements compared to one of the world's leading anti-seizure medications During Q1 2023, Lexaria expects to provide additional results from its hypertension study HYPER-H21-4; complete dosing in the company’s animal dementia and diabetes studies; complete dosing in the human nicotine study NIC-H21-1; and submit and publish additional results in research journals Lexaria’s DehydraTECH technology currently has 28 granted patents, with many more pending patents in countries worldwide Lexaria…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000